Biopharmaceutical, also known as a biologic (al) medical product, biological, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semi synthesized from biological sources. Cancer is a complex invasive genetic disease that causes significant mortality rate worldwide. Cancer drugs are the primary concern in terms of drug development trends.
This report contains market size and forecasts of Cancer Biopharmaceuticals in Global, including the following market information:
Global Cancer Biopharmaceuticals Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Cancer Biopharmaceuticals market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Biologics Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cancer Biopharmaceuticals include Sanofi, Johnson & Johnson, Pfizer, Novartis, Merck, GlaxoSmithKline, Eli Lilly, Agios Pharmaceuticals and Bristol-Myers Squibb, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cancer Biopharmaceuticals companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cancer Biopharmaceuticals Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Cancer Biopharmaceuticals Market Segment Percentages, by Type, 2021 (%)
Biologics
Biosimilars
Global Cancer Biopharmaceuticals Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Cancer Biopharmaceuticals Market Segment Percentages, by Application, 2021 (%)
Liquid Cancers
Solid Cancers
Global Cancer Biopharmaceuticals Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Cancer Biopharmaceuticals Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Biopharmaceuticals revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Cancer Biopharmaceuticals revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Johnson & Johnson
Pfizer
Novartis
Merck
GlaxoSmithKline
Eli Lilly
Agios Pharmaceuticals
Bristol-Myers Squibb
AstraZeneca
Mylan
LEO Pharma
Boehringer Ingelheim
Alexion Pharmaceuticals
Elusys Therapeutics